[go: up one dir, main page]

DK165004B - Sulfamatderivater og farmaceutiske praeparater indeholdende disse - Google Patents

Sulfamatderivater og farmaceutiske praeparater indeholdende disse Download PDF

Info

Publication number
DK165004B
DK165004B DK457784A DK457784A DK165004B DK 165004 B DK165004 B DK 165004B DK 457784 A DK457784 A DK 457784A DK 457784 A DK457784 A DK 457784A DK 165004 B DK165004 B DK 165004B
Authority
DK
Denmark
Prior art keywords
sulfamate
formula
sub
alkyl
hydrogen
Prior art date
Application number
DK457784A
Other languages
English (en)
Other versions
DK457784A (da
DK457784D0 (da
DK165004C (da
Inventor
Bruce Eliot Maryanoff
Joseph Francis Gardocki
Original Assignee
Mcneilab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24134409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK165004(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneilab Inc filed Critical Mcneilab Inc
Publication of DK457784D0 publication Critical patent/DK457784D0/da
Publication of DK457784A publication Critical patent/DK457784A/da
Priority to DK199101982A priority Critical patent/DK173923B1/da
Publication of DK165004B publication Critical patent/DK165004B/da
Application granted granted Critical
Publication of DK165004C publication Critical patent/DK165004C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Description

i
DK 165004 B
Sulfamater med forskellige strukturer, inklusive sådanne, der afledes af monosaccharider, er beskrevet i referencer såsom N.K.
Kochetkow, et al., i Zhurnal Obshchei Kimii, bind 41, nr. 8, 1866-1871 (1971), bind 42, nr. 12, 2755-2757 (1972) og bind 44, nr. 4, 871-875 5 (1974), og i Doklady Akademii Nauk SSR, bind 216, nr. 1, 97-100 (1974); T. Tsuchiya et al., i Tetrahedron Letters, nr. 36, 3365-3368 (1978); og A.F. Hirsch i Journal of Medicinal Chemistry, 24, 901-903 (1981), samt US-patentskrift nr. 4.075.351.
Det har nu vist sig, at sulfamater med formel (I) 10 Γ~x. .CH,OSO.NHR, ’•VN 111 R, Ri hvori X er 0 eller CH2 og Rj, R2, R3, R4 og Rg er som defineret i det 15 følgende, besidder anti-konvulsivisk aktivitet i pattedyr og derfor er anvendelige til behandling af sygdomstilstande såsom epilepsi og glau-kom. Den foreliggende opfindelse angår hidtil ukendte sulfamater med formlen (I) 2° r,^ch„, (i)
Rj hvori X er CH2 eller oxygen.
25 Rj er hydrogen eller al kyl, og
Rj>, R3, R4 og Rj, uafhængigt af hinanden, er hydrogen eller lavere alkyl og, når X er CH2, er R4 og Rg eventuelt alkengrupper, der tilsammen danner en benzenring og, når X er oxygen, danner R2 og R3 og/eller R4 og Rg eventuelt en methylendioxygruppe med formel (II) 30 (il) R, O- V- 35 hvori
Rg og R^, som er ens eller forskellige, er hydrogen, lavere al kyl eller al kyl, som tilsammen danner en cyclopentyl- eller cyclohexylring. Opfindelsen angår endvidere et farmaceutisk præparat, som er
DK 165004 B
2 ejendommeligt ved det i den kendetegnende del af krav 9 angivne.
Rj er især hydrogen eller al kyl med 1 til 4 carbonatomer såsom methyl, ethyl og isopropyl. I hele beskrivelsen betyder "alkyl" lige-kædede og forgrenede al kyl grupper. Specifikke alkylgrupper for R2, R3, 5 R4, Rg, Rg og Rj omfatter methyl, ethyl, isopropyl og n-propyl. Når X er CHg, kan R4 og Rg kombineres til dannelse af en benzenring, der er fusioneret til den 6-leddede, X-holdige ring, dvs. at R4 og Rg definerer al katrienylgruppen =CH-CH=CH-CH=.
En speciel gruppe forbindelser med formel (I) er sådanne, hvori X 10 er oxygen og både R2 og R3 og R4 og Rg tilsammen danner methyl endioxy-grupper med formel (II), hvori Rg og R7 begge er hydrogen og al kyl eller tilsammen danner en spiro-cyclopentyl- eller cyclohexylring, især, når Rg og R^ begge er al kyl såsom methyl. En anden gruppe forbindelser er sådanne, hvori X er CH2 og R4 og Rg danner en benzenring. En tredje 15 gruppe forbindelser med formel (I) er sådanne, hvori både R2 og R3 er hydrogen.
Forbindelserne med formel (I) kan syntetiseres ved hjælp af følgende fremgangsmåder: a) Omsætning af en alkohol med formlen RCHgOH med et chlorsulfamat 20 med formlen C1S02NH2 eller CISOgNHRj i nærværelse af en base såsom kalium-t-butoxid eller natriumhydrid ved en temperatur på ca. -20 til 25°C og i et opløsningsmiddel såsom toluen, THF eller dimethyl formamid, hvori R har formlen (III) p /"V (III)
25 R,vA
R, R, b) omsætning af en alkohol med formlen RCH20H med sulfurylchlorid med formlen S02C12 i nærværelse af en base såsom triethylamin eller 30 pyridin ved en temperatur på ca. -40 til 25°C i et opløsningsmiddel såsom diethyl ether eller methylenchlorid til dannelse af et chlorsulfat med formi en RCHgOSOgCl.
Chl orsulfatet med formlen RCH20$02C1 kan dernæst omsættes med en amin med formlen RjNH2 ved en temperatur på ca. -40 til 25°C i et opløs-35 ningsmiddel såsom methylenchlorid eller acetonitril til dannelse af en forbindelse med formel (I). Omsætningsbetingelserne for b) er også beskrevet af T. Tsuchiya, et al., i Tet. Letters, nr. 36, side 3365-3368 (1978).
DK 165004 B
3 c) Omsætning af chlorsulfatet RCHgOSOgCl med et metalazid såsom natriumazid i et opløsningsmiddel såsom methylenchlorid eller acetoni-tril giver et azidosulfat med formlen RCHgOSOgN^ som beskrevet af M.
Hedayatul1 ah i Tet. Lett., side 2455-2458 (1975). Az i dosulfatet reduce-5 res dernæst til en forbindelse med formel (I), hvori Rj er hydrogen, ved katalytisk hydrogenering, fx. med et ædelmetal og Hg eller ved opvarmning med kobbermetal i et opløsningsmiddel såsom methanol.
Udgangsforbindelserne med formlen RCHgOH kan fås kommercielt eller som kendt i teknikken. Eksempelvis kan udgangsforbindelser med formlen 10 RCHgOH, hvori både Rg og Rj og R^ og Rg er identiske og har formlen (II), opnås ved fremgangsmåderne ifølge R.F. Brady i Carbohydrate Research, bind 15, side 35-40 (1970), eller ved omsætning af trimethyl-silylenoletheren af en RgCOR^-keton eller -aldehyd med fruktose ved en temperatur på ca. 25°C i et opløsningsmiddel såsom et halogencarbon, fx.
15 methylenchlorid, i nærværelse af en protisk syre såsom saltsyre eller en Lewis-syre såsom zinkchlorid. Trimethylsilylenoletherreaktionen er beskrevet af G. L. Larson et al i J. Org. Chem., bind 38, nr. 22, side 3935 (1973).
Desuden kan carboxylsyrer og aldehyder med formlen RCOOH og RCHO 20 reduceres til forbindelser med formel RCHgOH ved standard-reduktionsteknikker, fx. omsætning med lithiumaluminiumhydrid, natriumborhydrid eller boran-THF-kompleks i et inert opløsningsmiddel såsom diglyme, THF eller toluen ved en temperatur fra ca. 0 til 100°C, fx. som beskrevet af H.O.
House i "Modern Synthetic Reactions", 2. oplag, side 45-144 (1972).
25 Forbindelserne ifølge opfindelsen omfatter forskellige individuelle isomere samt racematerne deraf, fx. de forskellige forbindelser, hvori Rg, Rj, R^ og Rg er bundet i alfa- eller beta-stilling i forhold til den 6-leddede ring, dvs. under og over tegningens plan. Fortrinsvis er methylendioxygruppens (II) oxygener bundet på samme side af den 6-30 leddede ring.
Forbindelserne med formel (I) er nyttige som antikonvulsiviske midler. Den antikonvulsiviske aktivitet af forbindelserne ifølge opfindelsen bestemtes under anvendelse af en standard "maksimal elektrochock-test" (MES). I denne test indikeres aktivitet ved en 35 blokering af den toniske ekstensor-spasme, der frembringes ved påføring af et elektrisk chock til mus via hornhindeelektroder som beskrevet af Swinyard, et al., i J. Pharmacol. Exptl. Therap. 106, 319 (1952), og anføres som % blokering. En nyere beskrivelse af nu-
DK 165004B
4 tidig antikonvulsivisk lægemiddel-screening kan findes i Swinyard, et al., Epilepsia 19, 409 (1978).
Den antikonvulsiviske aktivitet af forbindelser ifølge opfindelsen, der testes iht. Swinyard-metoden (1952), vises i den følgende tabel (I): 5
Tabel (I)
Eksempel Forbindelse MES-test EDgg *(mg/kg, i.p.) 1 /—o 19 5 10 / Vch,oso,nh, _. CH, 2 Ο-,Ο.Ο,ΝΗ, 270 15 . _o CHjOSOjNH, 3 ch>'Z/^Vch‘ 26 CH, CH· 20 J 0^pH,0S0,NHCH, 70% blok ved 200 mg/kgj i p CH, CH» ch2oso,nh, 5' \ / 55
25 K
*Medmindre andet er anført.
30 Til behandling af epilepsi kan der i et voksent gennemsnitsmenneske anvendes en forbindelse med formel (I) i en daglig dosering i området fra ca. 30 til 2000 mg, sædvanligvis i 2 til 4 doser. En enhedsdosis indeholder ca. 10 til 500 mg aktiv bestanddel.
Almindeligvis kan forbindelser med formel (I) anvendes til 35 behandling af epilepsi på en måde, der ligner den, der anvendes med phenytoin. Medicinske aspekter af behandlingen af epilepsi er beskrevet af L.S. Goodman, et al., i "The Pharmacological Basis of Therapeutics", 5. oplag, s. 201-226, Macmillan (1975).
5
Desuden inhiberer forbindelser med formel (I) carbonsyreanhydrase, som vist ved de af S.J. Dodgson. et al., i The Proc. Natl. Acad. Sci., USA, 77, s. 5562-5566 (1980) eller af N. Itada, et al., i The Journal Biol. Chem., 252, s. 3881-3890 (1977) beskrevne fremgangsmåder og er som 5 sådanne anvendelige til behandling af glaukom. Sammenhængen mellem behandling af glaukom og carbonsyreanhydrase-inhibering er beskrevet af A. Stein, et al., i The American Journal of Opthalmology, 95:222-228 (1983). Til behandling af glaukom kan en forbindelse med formel (I) administreres systemisk, fx. ad oral eller parenteral vej som beskrevet 10 nedenfor, eller topisk i øjet som en mineralolieopløsning eller -suspension, eller vandig suspension. Når forbindelsen anvendes systemisk, administreres den i en mængde fra ca. 50 til 500 mg per dag for et voksent gennemsnits-menneske, mens den topiske dosering er ca. 1 til 3 dråber (per øje) af en opløsning eller suspension, der indeholder ca. 1 til 15 5 vægt-% af en forbindelse med formel (I), idet dosen administreres ca.
1 til 4 gange daglig.
Til fremstilling af de farmaceutiske præparater ifølge opfindelsen blandes én eller flere sulfamatforbindel ser med formel (I) grundigt med en farmaceutisk bærer iht. konventionelle farmaceu-20 tiske sammenbland!ngsteknikker, idet bæreren kan være på mange forskellige former i afhængighed af den til administreringen ønskede præparatform, fx. oral, ved suppositorier eller parenteral. Ved fremstilling af præparaterne i oral dosisform kan der anvendes et hvilket som helst af de sædvanlige farmaceutiske medier. Egnede 25 bærere og tilsætningsstoffer for flydende orale præparater som fx suspensioner, elikserer og opløsninger omfatter således vand, gly-koler, olier, alkoholer, smagsstoffer, konserveringsmidler, farvestoffer o.l., for faste orale præparater såsom fx. pulvere, kapsler og tabletter omfatter egnede bærere og tilsætningsstoffer, stivelser, 30 sukkerarter, fortyndere, granuleringsmidler, smøremidler, bindemidler, disintegreringsmidler o.l. P.g.a. den lette administrering udgør tabletter og kapsler den mest fordelagtige orale enhedsdosisform, i hvilket tilfælde der selvfølgelig anvendes faste farmaceutiske bærere. Om ønsket kan tabletter sukkerovertrækkes eller overtræk-35 kes enterisk ved hjælp af standardteknikker. Der kan fremstilles suppositorier, i hvilket tilfælde kakaosmør kan anvendes som bærer.
Ved parenterale præparater omfatter bæreren sædvanligvis sterilt vand, selvom andre bestanddele kan inkluderes, fx med hensigten
DK 165004B
6 såsom at forbedre opløseligheden eller holdbarheden. Der kan også fremstilles injicerbare suspensioner, i hvilket tilfælde der kan anvendes passende flydende bærere, suspensionsmidler o.l.
Det farmaceutiske præparater ifølge opfindelsen vil pr. enheds-5 dosis fx. tabletter, kapsler, pulvere, injektioner, teskefuld, suppositorier o.l. indeholde fra ca. 10 til ca. 500 mg aktiv bestanddel.
De ovennævnte foregående præparater er specielt egnede til anvendelse ved behandling af epilepsi eller epilepsi-symptomer ved hjælp af en fremgangsmåde, der omfatter intern administrering til en 10 patient, der lider af epilepsi-symptomer, idet præparaterne omfatter en effektiv epilepsi-inhiberende mængde af en forbindelse med formel (I).
I de følgende eksempler og i hele beskrivelsen anvendes følgende forkortelser: g (gram), ml (milliliter), cm (centimeter), v/v (volumen til volumen), smp. (smeltepunkt), TLC (tyndtlagskromatografi), NMR 15 (kernemagnetisk resonans), IR (infrarød), DMF (dimethylformamid), THF (tetrahydrofuran) og C, Η, N, etc. (de kemiske symboler for grundstofferne).
Eksempel 1 20 (Tetrahydro-2H-pyran-2-yl)methansulfamat
Til en kold opløsning (-5°C) af tetrahydropyran-2-methanol (2,33 g, 0,02 mol) i DMF (40 ml) sattes 50% olieagtigt natriumhydrid (1,17 g, 0,024 mol som NaH). Efter omrøring i 45 minutter tilsattes sulfamoylchlorid (3,42 g, 0,03 mol) og omrøringen fortsattes i yderi ige-25 re 45 minutter ved -5°C. Reaktionsblandingen hældtes i koldt vand og ekstraheredes med chloroform. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en sirup, der kro-matograferedes på tør kolonne (der elueredes med ethyl acetat:hexan, 4:1 v/v), hvilket gav rent (tetrahydro-2H-pyran-2-yl)methansulfamat som en 30 svagt gul sirup, IR:(CHCl^) 1180 cm"1 og 1370 cm"1 (OSOgNHg).
Eksempel 2 (1-methylcyclohexyl)methansulfamat
Til en kold opløsning (-4°C) af (1-methylcyclohexyl)methanol (6,2 35 g, 0,048 mol) i DMF (90 ml) sattes 50% olieagtigt natriumhydrid (82,81 g, 0,059 mol som NaH). Efter omrøring i 1 time tilsattes sulfamoylchlo-rid (7,82 g, 0,062 mol) og omrøringen fortsattes i yderligere 30 minutter ved -4°C. Reaktionsblandingen hældtes i koldt vand og ekstraheredes
DK 165004 B
7 med toluen. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en sirup, der krystalliserede efter afkøling. Omkrystallisation fra chloroform/ hexan gav rent (1-methyl-cyclohexyljmethansulfamat, smp. 40-42°C.
5
Eksempel 3 2,3:4,5-bi s-0-(1-methyl ethyl i den)-β-O-fruktopyranosesulfamat
Til en kold opløsning (-4°C) af 2,3:4,5-di-0-isopropyliden-/3-fruk-topyranose (75 g, 0,29 mol) i DMF (725 ml) sattes 50% olieagtigt natri -10 umhydrid (16,34 g, 0,34 mol som NaH). Efter omrøring i 90 minutter tilsattes sulfamoylchlorid (54,9 g, 0,48 mol) og omrøringen fortsattes i yderligere 3½ time ved denne temperatur. Reaktionsblandingen hældtes i koldt vand og ekstraheredes med toluen. Det organiske lag tørredes (Na2S04) og opløsningsmidlerne fjernedes under vakuum, hvilket gav en 15 sirup, som øjeblikkeligt krystalliserede. Omkrystallisation fra ethyl -acetat/hexan gav rent 2,3:4,5-bis-0-(l-methylethyliden)-/J-D-fruktopyra-nosesulfamat, smp. 125-126°C.
Eksempel 4 20 2,3:4,5-bi s-0- (1 -methylethyl iden) -jS-D-fruktopyranosemethyl sul famat En opløsning af sulfonylchlorid (93 ml, 1,15 mol) i methylen-chlorid (100 ml) sattes dråbevis til en kold opløsning (-35°C) af 2,3:4,5-di-0-isopropyliden-/3-D-fruktopyranose (150 g, 0,58 mol) i methylenchlorid (400 ml) og pyridin (150 ml). Reaktionsblandingen 25 omrørtes og opvarmedes til stuetemperatur (25°C); den omrørtes i yderligere 2 timer. Opløsningsmidler fjernedes under vakuum. Det resulterende halvfaste stof opløstes i vandfri acetonitril (35 g, 150 ml) og methylamin bobledes igennem. Reaktionsbeholderen lukkedes tæt og opløsningsmidler fjernedes under vakuum. Den resulterende sirup 30 underkastedes væskekromatografi (tør kolonne ethyl acetat: hexan, 4:1), hvilket gav en lysegul sirup, 2,3:4,5-bis-0-(l-methylethyliden)-j3-D-fruktopyranosemethylsul famat, som var homogent ifølge TLC og *H NHR.
Eksempel 5 35 (l,2,3,4-tetrahydro-2-naphthalenyl)methylsulfamsyreester
Til en kold opløsning (-5°) af (l,2,3,4-tetrahydro-2-naphthalenyl)-methanol (7,1 g, 0,044 mol) i DMF (80 ml) sattes 50% olieagtigt natriumhydrid (2,56 g, 0,054 mol som NaH). Efter omrøring i 45 minutter

Claims (10)

1. Sul famater med formlen (I)
15 R ^“^CH.OSO^HR, (I) hvori R|1 Rj X er CH2 eller oxygen. Rj er hydrogen eller al kyl, og
20 R2, Rg, R4 og Rg uafhængigt af hinanden er hydrogen eller lavere alkyl og, når X er CH2, er R^ og Rg eventuelt alkengrupper, der tilsammen danner en benzenring og, når X er oxygen, danner R2 og Rg og/eller R^ og Rg eventuelt en methylendioxygruppe med formel (II)
25 V0_ <U> r{ \>- hvori Rg og Ry, som er ens eller forskellige, er hydrogen, lavere al kyl, eller al kyl som tilsammen danner en cyclopentyl- eller cyclohexylring. 30
2. Sulfamat ifølge krav 1, kendetegnet ved, at X er oxygen og R2 og Rg og R^ og Rg tilsammen danner methylendioxygrupper med formlen (II), hvor Rg og Ry er som defineret ovenfor.
3. Sulfamat ifølge krav 1, kendetegnet ved, at X er CH2 og R^ og Rg er alkengrupper, der tilsammen danner en benzenring. DK 165004B
4. Sulfamat ifølge krav 3, kendetegnet ved, at R2 og Rg er hydrogen.
5. Sulfamat ifølge krav 1, kendetegnet ved, at 5 alkylgruppen for Rj er al kyl med 1 til 4 carbonatomer, den lavere al kyl -gruppe for R2, Rg, R4 og Rg er al kyl med 1 til 3 carbonatomer og den lavere al kyl for Rg og R^ er alkyl med 1 til 3 carbonatomer.
6. Sulfamat ifølge krav 1, kendetegnet ved, at det er ud- 10 valgt fra gruppen bestående af (tetrahydro-2H-pyran-2-yl)methansulfamat, (1-methylcyclohexylJmethansulfamat, 2,3:4,5-bis-0-(l-methyl ethyl i den)-β-ΰ-fruktopyranosesulfamat, 2,3:4,5-bis-0-(l-methyl ethyl i den)-/1-D-fruktopyranosemethy1 sul famat, 15 og (1,2,3,4-tetrahydro-2-napthalenyl)methylsulfamsyreester.
7. Sulfamat ifølge krav 6, kendetegnet ved, at det er 2,3:4,5-bi s-0-(1-methylethyl iden)-β-Ό-fruktopyranosesulfamat. 20
8. Sulfamat ifølge krav 6, kendetegnet ved, at det er (1,2,3,4-tetrahydro-2-naphthalenylJmethylsulfamsyreester.
9. Farmaceutisk præparat, kendetegnet ved, at det 25 omfatter et sulfamat ifølge krav 1 og en farmaceutisk acceptabel bærer.
10. Farmaceutisk præparat ifølge krav 9, kendetegnet ved, at sulfamatet er til stede i en enhedsdosismængde fra ca. 10 til 500 mg sulfamat. 30
DK457784A 1983-09-26 1984-09-25 Sulfamatderivater og farmaceutiske praeparater indeholdende disse DK165004C (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53547583 1983-09-26
US06/535,475 US4513006A (en) 1983-09-26 1983-09-26 Anticonvulsant sulfamate derivatives

Publications (4)

Publication Number Publication Date
DK457784D0 DK457784D0 (da) 1984-09-25
DK457784A DK457784A (da) 1985-03-27
DK165004B true DK165004B (da) 1992-09-28
DK165004C DK165004C (da) 1993-02-08

Family

ID=24134409

Family Applications (3)

Application Number Title Priority Date Filing Date
DK457784A DK165004C (da) 1983-09-26 1984-09-25 Sulfamatderivater og farmaceutiske praeparater indeholdende disse
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat
DK198191A DK165003C (da) 1983-09-26 1991-12-09 Chlorsulfat

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199101982A DK173923B1 (da) 1983-09-26 1991-12-09 Azidosulfat
DK198191A DK165003C (da) 1983-09-26 1991-12-09 Chlorsulfat

Country Status (18)

Country Link
US (1) US4513006A (da)
EP (1) EP0138441B1 (da)
JP (2) JPS60109558A (da)
KR (1) KR920001775B1 (da)
AT (1) ATE36149T1 (da)
AU (1) AU564842B2 (da)
CA (1) CA1241951A (da)
DE (1) DE3473143D1 (da)
DK (3) DK165004C (da)
ES (1) ES536225A0 (da)
FI (1) FI79095C (da)
HU (1) HU194540B (da)
IE (1) IE57684B1 (da)
MX (1) MX9202630A (da)
NL (1) NL990025I2 (da)
NO (2) NO170280C (da)
NZ (1) NZ209494A (da)
ZA (1) ZA847550B (da)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792569A (en) * 1987-08-27 1988-12-20 Mcneilab, Inc. Anticonvulsant phenethyl sulfamates
PT94305B (pt) * 1989-06-12 1997-02-28 Robins Co Inc A H Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5194446A (en) * 1989-06-12 1993-03-16 A. H. Robins Company, Incorporated Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) * 1989-06-12 1993-12-28 A. H. Robins Company, Incorporated Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
US5192785A (en) * 1989-09-03 1993-03-09 A. H. Robins Company, Incorporated Sulfamates as antiglaucoma agents
US6011024A (en) 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
US6903084B2 (en) 1991-08-28 2005-06-07 Sterix Limited Steroid sulphatase inhibitors
US6476011B1 (en) 1991-08-28 2002-11-05 Sterix Limited Methods for introducing an estrogenic compound
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
DE69434652T2 (de) * 1993-12-23 2007-03-01 Ortho-Mcneil Pharmaceutical, Inc. Antikonvulsive pseudofructopyranose sulfamate
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
KR970027051A (ko) * 1995-11-02 1997-06-24 조규향 카바모일기를 포함하는 신규한 설파메이트 화합물
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ATE204167T1 (de) * 1996-06-28 2001-09-15 Ortho Mcneil Pharm Inc Antikonvulsive derivate zur behandlung von psoriasis
US5753693A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
AU3501697A (en) * 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
PT915697E (pt) * 1996-06-28 2003-02-28 Ortho Mcneil Pharm Inc Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade
SK284271B6 (sk) * 1996-10-08 2004-12-01 Ortho-Mcneil Pharmaceutical, Inc. Výroba liečiva na liečenie neuropatickej bolesti
JP3744089B2 (ja) * 1996-12-02 2006-02-08 富士電機ホールディングス株式会社 マグネトロンスパッタ成膜装置および成膜方法
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
CA2348017C (en) * 1998-10-20 2005-07-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
ES2217819T3 (es) 1998-11-17 2004-11-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados anticonvulsivos para el tratamiento de transtornos de estres post-traumaticos.
DE60015070T2 (de) * 1999-01-19 2006-01-05 Ortho-Mcneil Pharmaceutical, Inc. Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
AR022321A1 (es) * 1999-01-21 2002-09-04 Ortho Mcneil Pharm Inc Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
CZ295594B6 (cs) * 1999-02-01 2005-08-17 Ortho-Mcneil Pharmaceutical, Inc. Použití antikonvulzních derivátů pro výrobu léčiva pro léčbu bulimia nervosa
TR200103125T2 (tr) * 1999-02-08 2002-04-22 Ortho-Mcneil Pharmaceutical, Inc. Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
MY129238A (en) * 1999-02-17 2007-03-30 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in treating essential tremor
CZ20013061A3 (cs) * 1999-02-24 2002-06-12 University Of Cincinnati Pouľití sulfamátových derivátů pro léčbu poruch kontroly impulsů
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
JP2002541199A (ja) 1999-04-08 2002-12-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 脂質を下げることに有用な抗痙攣薬誘導体
NZ514812A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in lowering blood pressure
WO2000061140A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in maintaining weight loss
WO2000066108A2 (en) * 1999-04-30 2000-11-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating cocaine dependency
US6420369B1 (en) 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
WO2000072841A1 (en) * 1999-05-28 2000-12-07 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7553818B2 (en) * 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
CA2377330C (en) 1999-06-14 2009-11-24 Thomas Najarian Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7659256B2 (en) * 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
ATE284223T1 (de) * 1999-08-20 2004-12-15 Ortho Mcneil Pharm Inc Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
US7335650B2 (en) * 2000-01-14 2008-02-26 Sterix Limited Composition
SE0000601D0 (sv) 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1309324B1 (en) * 2000-07-07 2006-03-22 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
US6627653B2 (en) 2000-08-02 2003-09-30 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful for the treatment of depression
JP2004518718A (ja) * 2000-10-30 2004-06-24 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗糖尿病薬および抗痙攣薬を含んで成る併用療法
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
CN1477976A (zh) 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
PL365927A1 (en) 2000-11-30 2005-01-10 Pfizer Products Inc. Combination of gaba agonists and sorbitol dehydrogenase inhibitors
NZ548578A (en) * 2001-02-02 2008-03-28 Ortho Mcneil Pharm Inc Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
JP2004331502A (ja) * 2001-06-18 2004-11-25 Ortho Mcneil Pharmaceut Inc 視神経細胞保護剤
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US20030092636A1 (en) * 2001-11-06 2003-05-15 Silberstein Stephen D. Treatment and prevention of paresthesia comprising co-therapy with anticonvulsant derivatives and potassium
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
BR0307951A (pt) * 2002-02-26 2004-12-21 Ortho Mcneil Pharm Inc Co-terapia para o tratamento de enxaqueca compreendendo derivados de anticonvulsivantes e agentes antienxaqueca
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040029941A1 (en) * 2002-05-06 2004-02-12 Jennings Julianne E. Zonisamide use in obesity and eating disorders
US7060725B2 (en) * 2002-05-13 2006-06-13 Janssen Pharmaceutica N.V. Substituted sulfamate anticonvulsant derivatives
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20110043664A (ko) * 2002-05-17 2011-04-27 듀크 유니버시티 비만치료방법
EP1364649A1 (en) * 2002-05-23 2003-11-26 Cilag AG Adduct of topiramate and tramadol hydrochioride and uses thereof
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
DK1545546T3 (da) * 2002-09-13 2007-08-06 Motac Neuroscience Ltd Behandling af dyskinesi med 2,3-benzodiazepiner
CN100502856C (zh) * 2002-09-17 2009-06-24 默塔克神经科学有限公司 运动障碍的治疗
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
US7196209B2 (en) * 2002-10-31 2007-03-27 Ortho-Mcneil Pharmaceutical, Inc. Continuous process for the preparation of fructopyranose sulfamate derivatives
AU2003297639A1 (en) * 2002-12-02 2004-06-23 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
RU2005122008A (ru) * 2002-12-13 2006-02-10 Цилаг Аг (Ch) Препараты с контролируемым высвобождением, содержащие трамадол и топирамат
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
UA81657C2 (ru) * 2003-03-04 2008-01-25 Орто-Макнейл Фармасьютикел, Инк. Способ получения противосудорожных производных топирамата
WO2004089965A2 (en) * 2003-04-07 2004-10-21 Cipla Ltd Topiramate and processes for the preparation thereof
CA2522708C (en) 2003-04-29 2013-05-28 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2004108732A1 (en) * 2003-05-12 2004-12-16 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF 2,3:4,5-BIS-O(1-METHYLETHYLIDENE)-ß-D-FRUCTOPYRANOSE SULFAMATE
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
WO2005016306A2 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
EP1658048A2 (en) * 2003-08-22 2006-05-24 ALZA Corporation Stepwise delivery of topiramate over prolonged period of time
WO2005020961A1 (en) * 2003-08-28 2005-03-10 Sandoz Ag Pharmaceutical composition comprising anticonvulsant with taste mask coating
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
UA87467C2 (en) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
AU2004291081A1 (en) * 2003-11-14 2005-06-02 Alza Corporation Controlled release of topirimate in liquid dosage forms
DK1691811T3 (da) 2003-12-11 2014-10-20 Sunovion Pharmaceuticals Inc Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
JP2007517901A (ja) 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
US20050203287A1 (en) * 2004-03-11 2005-09-15 Chandrasekhar Batchu Process for the preparation of sulfamate derivatives
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2270243T3 (es) 2004-08-19 2007-04-01 Helm Ag Procedimiento para la preparacion de topiramato.
US20060276528A1 (en) * 2004-08-24 2006-12-07 Abdel-Magid Ahmed F Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
CN101257889A (zh) * 2005-05-25 2008-09-03 詹森药业有限公司 托吡酯的儿科制剂
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
EP1937646A1 (en) 2005-09-23 2008-07-02 Janssen Pharmaceutica N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
BRPI0616402A2 (pt) * 2005-09-23 2011-06-21 Janssen Pharmaceutica Nv moduladores de canabinóide de hexaidro-cicloeptapirazol
JP5162461B2 (ja) * 2005-09-23 2013-03-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヘキサヒドロシクロオクチルピラゾール系カンナビノイドモジュレーター
US20070088019A1 (en) * 2005-09-29 2007-04-19 Han-Cheng Zhang Macroheterocyclic compounds as kinase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ES2761812T3 (es) 2005-11-22 2020-05-21 Nalpropion Pharmaceuticals Inc Composición y métodos de aumento de la sensibilidad a la insulina
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
WO2007092456A2 (en) * 2006-02-03 2007-08-16 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191452A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of pain
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009529575A (ja) * 2006-03-10 2009-08-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としてのピリジン−含有大複素環式化合物
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
UY30288A1 (es) * 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
TW200812574A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
WO2007137167A2 (en) * 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
WO2008010231A2 (en) * 2006-05-26 2008-01-24 Alembic Limited A process for the purification of topiramate
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
SI2061458T1 (sl) * 2006-09-15 2015-04-30 Regents Of The University Of Minnesota Sestavki topiramata in metode za njihovo uporabo
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
CN101553204B (zh) 2006-12-04 2013-10-30 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
AR070949A1 (es) * 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
AU2008353491A1 (en) * 2008-03-26 2009-10-01 Janssen Pharmaceutica N.V. Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of N- ( ( (2S) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
WO2009158114A1 (en) * 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CA2758302C (en) * 2009-05-08 2014-12-02 Georgia State University Research Foundation, Inc. Compounds and compositions comprising cdk inhibitors and methods for treatment of cancer
EP2523557B1 (en) 2010-01-11 2019-09-25 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
CN102725301B (zh) 2010-02-05 2015-05-13 台湾神隆股份有限公司 用于制造和纯化托吡酯的方法
PT2858640T (pt) 2012-06-06 2020-06-30 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
ES2761407T3 (es) 2013-03-15 2020-05-19 Aprecia Pharmaceuticals LLC Forma de dosificación rápidamente dispersable de topiramato
CN103910770B (zh) * 2014-03-14 2017-01-04 天津南开允公医药科技有限公司 一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997585A (en) * 1974-12-30 1976-12-14 Ortho Pharmaceutical Corporation Aliphatic sulfamates

Also Published As

Publication number Publication date
FI79095C (fi) 1989-11-10
AU3350484A (en) 1985-04-04
DK198291D0 (da) 1991-12-09
DK173923B1 (da) 2002-02-18
HUT36784A (en) 1985-10-28
FI843765L (fi) 1985-03-27
IE57684B1 (en) 1993-02-24
KR920001775B1 (ko) 1992-03-02
NO843836L (no) 1985-03-27
ES8602634A1 (es) 1985-11-16
DK165003C (da) 1993-02-08
DK198191A (da) 1991-12-09
ZA847550B (en) 1986-05-28
DK165003B (da) 1992-09-28
NZ209494A (en) 1987-03-06
AU564842B2 (en) 1987-08-27
CA1241951A (en) 1988-09-13
DK457784A (da) 1985-03-27
IE842444L (en) 1985-03-26
FI843765A0 (fi) 1984-09-25
EP0138441B1 (en) 1988-08-03
FI79095B (fi) 1989-07-31
JPH05331132A (ja) 1993-12-14
DK457784D0 (da) 1984-09-25
ATE36149T1 (de) 1988-08-15
NO170280C (no) 1992-09-30
JPS60109558A (ja) 1985-06-15
HU194540B (en) 1988-02-29
MX9202630A (es) 1992-06-30
NO170280B (no) 1992-06-22
DK198291A (da) 1991-12-09
NL990025I1 (nl) 1999-11-01
DK165004C (da) 1993-02-08
ES536225A0 (es) 1985-11-16
EP0138441A3 (en) 1986-08-27
DE3473143D1 (de) 1988-09-08
NO1997004I1 (no) 1997-05-09
JPH055824B2 (da) 1993-01-25
NL990025I2 (nl) 1999-12-01
US4513006A (en) 1985-04-23
EP0138441A2 (en) 1985-04-24
KR850002264A (ko) 1985-05-10
DK198191D0 (da) 1991-12-09

Similar Documents

Publication Publication Date Title
DK165004B (da) Sulfamatderivater og farmaceutiske praeparater indeholdende disse
US4792569A (en) Anticonvulsant phenethyl sulfamates
KR100241860B1 (ko) 약제학적으로 유용한 항경련제 설파메이트의 이미데이트 유도체
EP0568306B1 (en) Anticonvulsant fructopyranose cyclic sulfites and sulfates
EP0370415B1 (de) Quinuclidine, ihre Verwendung als Arzneimittel und Verfahren zu ihrer Herstellung
US5384327A (en) Anticonvulsant sorbopyranose sulfamates
CA1252109A (en) Anticonvulsant dioxolane methane sulfamates
US4582916A (en) Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
DE69524186T2 (de) Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE69605856T2 (de) Alkoxyarylverbindungen mit Affinität zu den Melatoninrezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
RU2139875C1 (ru) Сульфаматы псевдофруктопиранозы и фармацевтическая композиция на их основе
DE69227366T2 (de) Durch 2- und 5- Alkyl und Phenyl substituierte 4-(1-hydroxy, 1-acyloxy oder 1-carbamoyloxy)-5-hydroxy-2(5H)-Furanone als antiinflammatorische Mittel
US4797391A (en) ((5,6-dichloro-3-oxo-9,9a-disubstituted-2,3,9,9a-tetrahydrofluoren-7-yl)oxy)alkanoic acids and alkanimidamides
US4673668A (en) Aminonaphthacene derivatives
US4775695A (en) Substituted amidinoalkoxy and amidinoalkylamino indanones and salts thereof
DE60005300T2 (de) 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren
Nelson et al. Stereochemical analogs of a muscarinic, ganglionic stimulant. 2. The cis and trans olefinic, epoxide, and cyclopropane analogs related to 4-[N-(3-chlorophenyl) carbamoyloxy]-2-butynyltrimethylammonium chloride
US4312882A (en) Thienyoxy and furyl containing analogs of prostacyclin and their use as medicaments
EP0001270A1 (de) Neue Prostacyclin-Analoga, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Behandlung von Herzkreislauf-Krankheiten
US4241052A (en) Novel nitrosourea compounds and process for preparing the same
US5264559A (en) Azoxy compounds
RU2024515C1 (ru) Способ получения полициклических биоцидных соединений или их солей
US3991188A (en) 3-Alkyl-4-sulfamoyl-aniline therapeutic compositions
US4810727A (en) Chrysene compound
EP0383239A1 (de) Isomere Dideoxynucleoside, ihre Herstellung und Verwendung für Heilmittel

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1997 00014, 970228

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1997 00014, 970228, EXPIRES: 20090925

PUP Patent expired